Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Rituximab for EBV+ PTLD
NCT01058239Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2011
- Primary completion
- Dec 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in Post-transplant lymphoproliferative disease (PTLD), sponsored by Massachusetts General Hospital. Started Nov 2011; status: completed.
02
Drugs
bortezomib
03
Conditions
Post-transplant lymphoproliferative disease (PTLD)
Beyond the preview
Go deeper on NCT01058239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01058239.